Literature DB >> 25412935

Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies.

Daye Cheng1, Ying Sun, Hu He.   

Abstract

In the past decade, several studies have suggested a possible link between circulating YKL-40 levels and endometrial carcinoma (EC), but have arrived at inconsistent results. Therefore, we conducted the present meta-analysis and aim to disclose a more comprehensive evaluation of the sensitivity, specificity, and diagnostic accuracy of YKL-40 in EC. We systematically searched PubMed, Embase, Web of Science, Science Direct, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure databases for studies that evaluated the diagnostic value of YKL-40 in endometrial cancer. The STATA software 12.0 and Meta-Disc software were used to test the heterogeneity and to evaluate the overall test performance. A total of seven studies including 234 EC cases and 300 controls were included in our meta-analysis. The summary estimates of YKL-40 for EC diagnosis indicated a moderately high diagnostic accuracy for circulating YKL-40, with a sensitivity of 0.74, a specificity of 0.87, a PLR of 5.74, a NLR of 0.30, a DOR of 19.14, and an AUC of 0.80. On the basis of our meta-analysis, therefore, circulating YKL-40 could be promising and meaningful in the diagnosis of EC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412935     DOI: 10.1007/s12032-014-0326-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  30 in total

1.  The diagnostic odds ratio: a single indicator of test performance.

Authors:  Afina S Glas; Jeroen G Lijmer; Martin H Prins; Gouke J Bonsel; Patrick M M Bossuyt
Journal:  J Clin Epidemiol       Date:  2003-11       Impact factor: 6.437

Review 2.  Chronic inflammation and cancer: suppressing the suppressors.

Authors:  Michal Baniyash; Moshe Sade-Feldman; Julia Kanterman
Journal:  Cancer Immunol Immunother       Date:  2013-08-29       Impact factor: 6.968

3.  Serum and tissue level of YKL-40 in endometrial cancer.

Authors:  J T Fan; M J Li; P Shen; H Xu; D H Li; H Q Yan
Journal:  Eur J Gynaecol Oncol       Date:  2014       Impact factor: 0.196

4.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

5.  Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.

Authors:  Ina Thöm; Birte Andritzky; Gunter Schuch; Iris Burkholder; Lutz Edler; Julia S Johansen; Carsten Bokemeyer; Udo Schumacher; Eckart Laack
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

6.  Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Authors:  Catherine S M Diefenbach; Zharna Shah; Alexia Iasonos; Richard R Barakat; Douglas A Levine; Carol Aghajanian; Paul Sabbatini; Martee L Hensley; Jason Konner; William Tew; David Spriggs; Martin Fleisher; Howard Thaler; Jakob Dupont
Journal:  Gynecol Oncol       Date:  2006-10-04       Impact factor: 5.482

7.  Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.

Authors:  Xiaomei Liu; Yinxu Zhang; Zhitu Zhu; Minwen Ha; Yu Wang
Journal:  Med Oncol       Date:  2014-07-05       Impact factor: 3.064

8.  Serum YKL-40 as a marker for cervical adenocarcinoma.

Authors:  A Mitsuhashi; H Matsui; H Usui; Y Nagai; S Tate; Y Unno; K Hirashiki; K Seki; M Shozu
Journal:  Ann Oncol       Date:  2008-08-22       Impact factor: 32.976

9.  High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer.

Authors:  Dong Wang; Bo Zhai; Fengli Hu; Chang Liu; Jinpeng Zhao; Jun Xu
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

10.  Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Authors:  Nicolai A Schultz; Ib J Christensen; Jens Werner; Nathalia Giese; Benny V Jensen; Ole Larsen; Jon K Bjerregaard; Per Pfeiffer; Dan Calatayud; Svend E Nielsen; Mette K Yilmaz; Niels H Holländer; Morten Wøjdemann; Stig E Bojesen; Kaspar R Nielsen; Julia S Johansen
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more
  2 in total

1.  Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study.

Authors:  Tonia Adamidi; Nikolaos Soulitzis; Eirini Neofytou; Savvas Zannetos; Andreas Georgiou; Kleomenis Benidis; Alexis Papadopoulos; Nikolaos M Siafakas; Sophia E Schiza
Journal:  BMC Pulm Med       Date:  2015-12-01       Impact factor: 3.317

2.  Ykl-40 and cancer antigen 72-4 as new and promising diagnostic and prognostic markers for endometrial cancer.

Authors:  Suat Karataş; Veysel Şal; İlker Kahramanoğlu; Fuat Demirkıran; Tugan Beşe; Macit Arvas; Nigar Sofiyeva; Onur Güralp; Hafize Uzun
Journal:  Turk J Obstet Gynecol       Date:  2019-01-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.